# MAP3K12

## Overview
MAP3K12, also known as dual leucine zipper kinase (DLK), is a gene that encodes a serine/threonine kinase involved in the mitogen-activated protein kinase (MAPK) signaling pathway. The protein product, mitogen-activated protein kinase kinase kinase 12, is a member of the Mixed Lineage Kinase (MLK) family, characterized by its hybrid kinase domain that combines features of both serine/threonine and tyrosine kinases (Chen2016Leucine). This kinase plays a pivotal role in cellular processes such as proliferation, apoptosis, and stress responses, particularly within neuronal and pancreatic beta cells (Patel2014Discovery; Tenenbaum2020The). MAP3K12 is involved in the activation of the c-Jun N-terminal kinase (JNK) pathway, influencing various physiological and pathological conditions, including neurodegenerative diseases, cancer, and diabetes (Nguyen2022MAP3K; Patel2017Selective). The protein's activity is regulated through interactions with other proteins and post-translational modifications, such as phosphorylation and palmitoylation, which are crucial for its function in signaling pathways (Holland2015Palmitoylation; Duque2021Regulation).

## Structure
MAP3K12, also known as dual leucine zipper kinase (DLK), is a serine/threonine kinase involved in the MAPK signaling pathway. The protein features a leucine zipper domain that facilitates dimerization, which is crucial for its activation. This domain is shared with the closely related MAP3K13, with which it shares approximately 90% amino acid sequence identity in the kinase and leucine zipper domains (Chen2016Leucine). The kinase domain of MAP3K12 is a hybrid between serine/threonine and tyrosine protein kinases, classifying it as a member of the Mixed Lineage Kinase (MLK) family (Chen2016Leucine).

MAP3K12 undergoes phosphorylation as a post-translational modification, which is essential for its role in the MAPK signaling cascade. This modification typically occurs at specific motifs within the activation loop of the kinase domain, a common feature among kinases that facilitates their enzymatic activity (Taj2010MAPK). The protein's structure allows it to interact with other components of the MAPK pathway, influencing processes such as neuronal degeneration and axonal responses to injury (Patel2014Discovery).

Alternative splicing of MAP3K12 can result in different isoforms, which may affect its function and interactions, although specific details on these isoforms are not provided in the available context.

## Function
MAP3K12, also known as dual leucine zipper kinase (DLK), is a serine/threonine kinase that plays a significant role in the MAPK signaling pathway. It is a key upstream component of the c-Jun N-terminal kinase (JNK) pathway, specifically activating JNK3, which is involved in various cellular processes such as proliferation and apoptosis (Tenenbaum2020The). In pancreatic beta-cells, MAP3K12 is crucial for proliferation during postnatal development, as it regulates the expression of cyclins CCND1 and CCND2, which are essential for cell cycle progression (Tenenbaum2020The). The expression of MAP3K12 is upregulated in conditions requiring increased beta-cell mass, such as obesity and pregnancy, indicating its role in adapting to physiological demands (Tenenbaum2020The).

In the context of neuronal cells, MAP3K12 is involved in the regulation of neuronal degeneration and stress responses. It activates the JNK/c-Jun pathway, which is essential for the neuronal stress response and is implicated in neurodegenerative diseases (Patel2017Selective). MAP3K12 is active in both the cytoplasm and nucleus, influencing processes like axon growth and regeneration (Patel2014Discovery).

## Clinical Significance
MAP3K12, also known as dual leucine zipper kinase (DLK), plays a significant role in various diseases due to its involvement in the MAPK signaling pathway. Alterations in MAP3K12 expression have been linked to neurodegenerative diseases such as Alzheimer's Disease and Amyotrophic Lateral Sclerosis (ALS). Inhibition of MAP3K12 has shown potential in reducing synapse loss and neuronal degeneration in models of these diseases, suggesting its role as a therapeutic target (Patel2017Selective).

In cancer, MAP3K12 expression is associated with different outcomes depending on the cancer type. It is upregulated in T-cell acute lymphoblastic leukemia (T-ALL) and has been correlated with poor survival in kidney renal clear cell carcinoma and other cancers (Nguyen2022MAP3K). In prostate cancer, targeting MAP3K12 with microRNA miR-150-5p has been shown to suppress cell proliferation and invasion (Nguyen2022MAP3K).

MAP3K12 is also implicated in diabetes mellitus, where its dysregulation affects endothelial progenitor cell function, contributing to endothelial dysfunction. This is mediated through the JNK signaling pathway, which is activated by high glucose conditions typical in diabetes (Ye2015MicroRNA130a). Additionally, MAP3K12 is involved in ischemic stroke, where its expression is increased, leading to oxidative stress and memory dysfunction (Wang2021Celastrol).

## Interactions
MAP3K12, also known as DLK, is involved in several protein interactions that are crucial for its function in cellular signaling pathways. It physically interacts with MAPK10 (JNK3), forming a complex that is essential for pancreatic beta-cell proliferation. This interaction is confirmed through co-immunoprecipitation experiments, indicating that MAP3K12 acts as a strong activator of the MAPK signaling pathway, which includes c-Jun amino terminal kinases (JNK) (Tenenbaum2020The).

MAP3K12 also interacts with calcineurin, a calcium/calmodulin-dependent phosphatase, through a specific φLxVP motif. This interaction is crucial for regulating MAP3K12's activity, as it affects the phosphorylation of MAP3K12 and its downstream targets, such as JNK. Mutations in this motif can disrupt the interaction, leading to altered MAP3K12 activity and increased apoptosis in pancreatic beta cells (Duque2021Regulation).

Palmitoylation of MAP3K12 is another critical factor that influences its interactions. This post-translational modification allows MAP3K12 to form complexes with JIP3 and MAP2Ks like MKK4 and MKK7, which are necessary for effective axonal injury signaling. These interactions are palmitoylation-dependent, highlighting the importance of this modification in MAP3K12's role in neuronal signaling (Holland2015Palmitoylation).


## References


[1. (Tenenbaum2020The) Mathie Tenenbaum, Valérie Plaisance, Raphael Boutry, Valérie Pawlowski, Cécile Jacovetti, Clara Sanchez-Parra, Hélène Ezanno, Julien Bourry, Nicole Beeler, Gianni Pasquetti, Valery Gmyr, Stéphane Dalle, Julie Kerr-Conte, François Pattou, Syu-ichi Hirai, Romano Regazzi, Amélie Bonnefond, Philippe Froguel, and Amar Abderrahmani. The map3k12 (dlk)/jnk3 signaling pathway is required for pancreatic beta-cell proliferation during postnatal development. Cellular and Molecular Life Sciences, 78(1):287–298, March 2020. URL: http://dx.doi.org/10.1007/s00018-020-03499-7, doi:10.1007/s00018-020-03499-7. This article has 13 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s00018-020-03499-7)

[2. (Taj2010MAPK) Gohar Taj, Payal Agarwal, Murray Grant, and Anil Kumar. Mapk machinery in plants: recognition and response to different stresses through multiple signal transduction pathways. Plant Signaling &amp; Behavior, 5(11):1370–1378, November 2010. URL: http://dx.doi.org/10.4161/psb.5.11.13020, doi:10.4161/psb.5.11.13020. This article has 206 citations.](https://doi.org/10.4161/psb.5.11.13020)

[3. (Patel2014Discovery) Snahel Patel, Frederick Cohen, Brian J. Dean, Kelly De La Torre, Gauri Deshmukh, Anthony A. Estrada, Arundhati Sengupta Ghosh, Paul Gibbons, Amy Gustafson, Malcolm P. Huestis, Claire E. Le Pichon, Han Lin, Wendy Liu, Xingrong Liu, Yichin Liu, Cuong Q. Ly, Joseph P. Lyssikatos, Changyou Ma, Kimberly Scearce-Levie, Young G. Shin, Hilda Solanoy, Kimberly L. Stark, Jian Wang, Bei Wang, Xianrui Zhao, Joseph W. Lewcock, and Michael Siu. Discovery of dual leucine zipper kinase (dlk, map3k12) inhibitors with activity in neurodegeneration models. Journal of Medicinal Chemistry, 58(1):401–418, October 2014. URL: http://dx.doi.org/10.1021/jm5013984, doi:10.1021/jm5013984. This article has 69 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1021/jm5013984)

[4. (Chen2016Leucine) Meifan Chen, Cédric G. Geoffroy, Hetty N. Wong, Oliver Tress, Mallorie T. Nguyen, Lawrence B. Holzman, Yishi Jin, and Binhai Zheng. Leucine zipper-bearing kinase promotes axon growth in mammalian central nervous system neurons. Scientific Reports, August 2016. URL: http://dx.doi.org/10.1038/srep31482, doi:10.1038/srep31482. This article has 31 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/srep31482)

[5. (Wang2021Celastrol) Chaoyun Wang, Hongzhi Wan, Miao Li, and Chunxiang Zhang. Celastrol attenuates ischemia/reperfusion-mediated memory dysfunction by downregulating ak005401/map3k12. Phytomedicine, 82:153441, February 2021. URL: http://dx.doi.org/10.1016/j.phymed.2020.153441, doi:10.1016/j.phymed.2020.153441. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.phymed.2020.153441)

[6. (Holland2015Palmitoylation) Sabrina M. Holland, Kaitlin M. Collura, Andrea Ketschek, Kentaro Noma, Toby A. Ferguson, Yishi Jin, Gianluca Gallo, and Gareth M. Thomas. Palmitoylation controls dlk localization, interactions and activity to ensure effective axonal injury signaling. Proceedings of the National Academy of Sciences, 113(3):763–768, December 2015. URL: http://dx.doi.org/10.1073/pnas.1514123113, doi:10.1073/pnas.1514123113. This article has 96 citations.](https://doi.org/10.1073/pnas.1514123113)

[7. (Duque2021Regulation) J. Duque Escobar, Anna Kutschenko, Sabine Schröder, Roland Blume, Kyra-Alexandra Köster, Christina Painer, Thomas Lemcke, Wolfgang Maison, and Elke Oetjen. Regulation of dual leucine zipper kinase activity through its interaction with calcineurin. Cellular Signalling, 82:109953, June 2021. URL: http://dx.doi.org/10.1016/j.cellsig.2021.109953, doi:10.1016/j.cellsig.2021.109953. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.cellsig.2021.109953)

[8. (Ye2015MicroRNA130a) Meng Ye, Dan Li, Jian Yang, Jing Xie, Fei Yu, Yushui Ma, Xuchao Zhu, Jinwei Zhao, and Zhongwei Lv. Microrna-130a targets map3k12 to modulate diabetic endothelial progenitor cell function. Cellular Physiology and Biochemistry, 36(2):712–726, 2015. URL: http://dx.doi.org/10.1159/000430132, doi:10.1159/000430132. This article has 29 citations and is from a peer-reviewed journal.](https://doi.org/10.1159/000430132)

[9. (Nguyen2022MAP3K) Khoa Nguyen, Minh N. Tran, Andrew Rivera, Thomas Cheng, Gabrielle O. Windsor, Abraham B. Chabot, Jane E. Cavanaugh, Bridgette M. Collins-Burow, Sean B. Lee, David H. Drewry, Patrick T. Flaherty, and Matthew E. Burow. Map3k family review and correlations with patient survival outcomes in various cancer types. Frontiers in Bioscience-Landmark, 27(5):167, May 2022. URL: http://dx.doi.org/10.31083/j.fbl2705167, doi:10.31083/j.fbl2705167. This article has 11 citations.](https://doi.org/10.31083/j.fbl2705167)

[10. (Patel2017Selective) Snahel Patel, William J. Meilandt, Rebecca I. Erickson, Jinhua Chen, Gauri Deshmukh, Anthony A. Estrada, Reina N. Fuji, Paul Gibbons, Amy Gustafson, Seth F. Harris, Jose Imperio, Wendy Liu, Xingrong Liu, Yichin Liu, Joseph P. Lyssikatos, Changyou Ma, Jianping Yin, Joseph W. Lewcock, and Michael Siu. Selective inhibitors of dual leucine zipper kinase (dlk, map3k12) with activity in a model of alzheimer’s disease. Journal of Medicinal Chemistry, 60(19):8083–8102, September 2017. URL: http://dx.doi.org/10.1021/acs.jmedchem.7b00843, doi:10.1021/acs.jmedchem.7b00843. This article has 45 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1021/acs.jmedchem.7b00843)